Comprehensive Molecular Docking and Molecular Dynamics Reveal Inhibitors of HER2 L755S, T798I, and T798M based on a...

This study presents a methodology employing virtual screening to identify curcumin derivatives with selective affinity for the HER2 mutations L755S, T798I, and T798M.

Curcumin derivatives were retrieved from the ChEMBL database and filtered using KNIME. HER2 mutations were modeled in silico using MOE software with PDB ID 3RCD. Molecular docking and dynamics simulations were conducted to screen high-affinity compounds and evaluate binding interactions.

From 505 curcumin derivatives, the RDKit module implemented in KNIME successfully filtered 317 compounds. Subsequent molecular docking against wild-type HER2 identified 100 curcumin derivatives with low docking scores, among which the top 20 compounds exhibited better binding affinities than Lapatinib. Further molecular docking screening against the three HER2 mutations identified five lead compounds with the lowest docking scores. Molecular docking and molecular dynamics simulation revealed critical binding interactions with residues essential for kinase domain stability. Chemical structural analysis revealed key modifications, such as geranyl and tripeptide modifications. CHEMBL3758656 and CHEMBL3827366, two curcumin derivatives, demonstrated consistent binding across HER2 mutations and a favorable ADMET profile.

This study successfully identified CHEMBL3758656 and CHEMBL3827366 as promising HER2 inhibitors through comprehensive virtual screening. Their high binding affinity against L755S, T798I, and T798M mutations and favorable ADME and toxicity properties underscore their potential as alternative therapeutics for HER2-positive breast cancer.